| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GZMH |
| Uniprot No | P20718 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-246aa |
| 氨基酸序列 | IIGGHEAKPH SRPYMAFVQF LQEKSRKRCG GILVRKDFVL TAAHCQGSSI NVTLGAHNIK EQERTQQFIP VKRPIPHPAY NPKNFSNDIM LLQLERKAKW TTAVRPLRLP SSKAQVKPGQ LCSVAGWGYV SMSTLATTLQ EVLLTVQKDC QCERLFHGNY SRATEICVGD PKKTQTGFKG DSGGPLVCKD VAQGILSYGN KKGTPPGVYI KVSHFLPWIK RTMKRL |
| 预测分子量 | 28 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于 **GZMH(颗粒酶H)重组蛋白** 的示例参考文献(内容为模拟，非真实文献)：
1. **文献名称**: *Structural and functional characterization of recombinant human granzyme H*
**作者**: Smith A, et al.
**摘要**: 研究通过大肠杆菌系统表达并纯化重组GZMH蛋白，解析其晶体结构，发现其底物结合位点的特异性，验证其在体外诱导肿瘤细胞凋亡的功能。
2. **文献名称**: *GZMH modulates antiviral immunity via cleavage of viral RNA-binding proteins*
**作者**: Chen L, et al.
**摘要**: 利用哺乳动物细胞表达重组GZMH，证明其通过切割宿主细胞内的病毒RNA结合蛋白(如La抗原)，抑制病毒复制，揭示了GZMH在抗病毒免疫中的新机制。
3. **文献名称**: *Recombinant GZHM as a potential biomarker in chronic inflammation*
**作者**: Wang Y, et al.
**摘要**: 通过HEK293细胞系统制备重组GZMH，分析其在类风湿性关节炎患者血清中的表达水平升高，提示其可作为炎症性疾病的潜在诊断标志物。
4. **文献名称**: *Engineering protease-resistant GZMH variants for therapeutic applications*
**作者**: Kim J, et al.
**摘要**: 通过定点突变技术优化重组GZMH蛋白的稳定性，增强其在体内的半衰期，为基于GZMH的靶向肿瘤治疗提供新策略。
---
**注**: 以上文献为模拟生成，实际研究中建议通过 **PubMed/Google Scholar** 检索真实文献(关键词：GZMH, recombinant protein, granzyme H)。
**Background of Recombinant GZMH Protein**
Granzyme H (GZMH) is a serine protease belonging to the granzyme family, primarily secreted by cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. It is stored in cytotoxic granules alongside perforin and other granzymes, playing a critical role in immune-mediated apoptosis of virus-infected or malignant cells. Unlike the well-characterized granzyme B (GZMB), which directly cleaves caspases to trigger apoptosis, GZMH exhibits distinct substrate specificity and may contribute to alternative cell death pathways or immune modulation, though its precise mechanisms remain under investigation.
Recombinant GZMH protein is engineered using heterologous expression systems, such as *E. coli* or mammalian cell lines, to produce purified, bioactive forms for research. This involves cloning the GZMH gene into expression vectors, optimizing conditions for proper folding (e.g., inclusion of chaperones for prokaryotic systems), and employing affinity chromatography (e.g., His-tag purification) to ensure high purity. Post-translational modifications, critical for enzymatic activity, often necessitate eukaryotic expression systems.
Studies leveraging recombinant GZMH focus on elucidating its role in immunity and disease. It is implicated in antiviral responses, cancer immunosurveillance, and inflammatory disorders. For example, GZMH-deficient models suggest compensatory interactions with other granzymes, while overexpression studies link it to unique apoptotic pathways. Additionally, recombinant GZMH serves as a tool to screen inhibitors or biomarkers for therapeutic development, particularly in immunotherapies targeting CTL/NK cell dysfunction.
Despite progress, challenges persist in defining its physiological substrates and regulatory mechanisms. Ongoing research aims to clarify its dual roles in promoting cell death and regulating non-cytotoxic immune functions, highlighting its potential as a therapeutic target or diagnostic marker in immune-related pathologies.
×
